RegulatoryJun 18, 2026, 05:06 PM
Actinium Pharmaceuticals Submits NYSE American Compliance Plan
AI Summary
Actinium Pharmaceuticals, Inc. submitted a compliance plan to NYSE American on June 18, 2026. This plan outlines actions to restore compliance with the exchange's listing standards, specifically Section 1003(a)(ii). The company had previously received a notice on May 27, 2026, indicating non-compliance due to not maintaining stockholders' equity of $4.0 million or more, having reported losses in three of its four most recent fiscal years.
Key Highlights
- Actinium Pharmaceuticals submitted a compliance plan to NYSE American on June 18, 2026.
- The plan addresses non-compliance with NYSE American listing standards Section 1003(a)(ii).
- The standard requires maintaining stockholders' equity of $4.0 million or more.
- Company reported losses from continuing operations and/or net losses in three of its four most recent fiscal years.
- A notice of non-compliance was previously received on May 27, 2026.
Price Impact
More from ATNM